BACKGROUND: Development of resistance to anticancer drugs is a major concern in clinical oncology and might be particularly involved in the secondary treatment failure frequently seen in ovarian cancer. Clinical observation of the multidrug resistance (MDR) phenotype is often associated with overexpression of the mdr1-gene. However, until now the mdr1-inducing potential of commonly used antineoplastics has been only incompletely explored. MATERIALS AND METHODS: We perfomed short-term cultures of 7 established ovarian cancer cell lines exposed to either blank medium or one of three single anticancer drugs (cisplatin, doxorubicin, paclitaxel) at concentrations related to the clinically achievable plasma peak concentration. Mdr1-transcripts were detected using the highly specific quantitative real time RT-PCR. To calibrate each approach, mdr1-mRNA content was calculated in relation to co-amplified GAPDH-mRNA. RESULTS: Mdr1-mRNA was detectable in each cell line. In 13 assays (62%) the specific anticancer drug being tested induced mdr1-transcription. No decrease in mdr1-mRNA concentration was observed. The method described here is easy to perform and could be of striking value in predicting the development of tumor chemoresistance. CONCLUSION: Our data indicate that mdr1-induction by antineoplastics is one of the reasons for failure of ovarian cancer therapy but may vary from one individual to another.
BACKGROUND: Development of resistance to anticancer drugs is a major concern in clinical oncology and might be particularly involved in the secondary treatment failure frequently seen in ovarian cancer. Clinical observation of the multidrug resistance (MDR) phenotype is often associated with overexpression of the mdr1-gene. However, until now the mdr1-inducing potential of commonly used antineoplastics has been only incompletely explored. MATERIALS AND METHODS: We perfomed short-term cultures of 7 established ovarian cancer cell lines exposed to either blank medium or one of three single anticancer drugs (cisplatin, doxorubicin, paclitaxel) at concentrations related to the clinically achievable plasma peak concentration. Mdr1-transcripts were detected using the highly specific quantitative real time RT-PCR. To calibrate each approach, mdr1-mRNA content was calculated in relation to co-amplified GAPDH-mRNA. RESULTS:Mdr1-mRNA was detectable in each cell line. In 13 assays (62%) the specific anticancer drug being tested induced mdr1-transcription. No decrease in mdr1-mRNA concentration was observed. The method described here is easy to perform and could be of striking value in predicting the development of tumor chemoresistance. CONCLUSION: Our data indicate that mdr1-induction by antineoplastics is one of the reasons for failure of ovarian cancer therapy but may vary from one individual to another.
Authors: Stefan Buchholz; Gunhild Keller; Andrew V Schally; Gabor Halmos; Florian Hohla; Elmar Heinrich; Frank Koester; Benjamin Baker; Jörg B Engel Journal: Proc Natl Acad Sci U S A Date: 2006-06-26 Impact factor: 11.205
Authors: Hans C Arora; Mark P Jensen; Ye Yuan; Aiguo Wu; Stefan Vogt; Tatjana Paunesku; Gayle E Woloschak Journal: Cancer Res Date: 2011-12-12 Impact factor: 12.701
Authors: Lihong Mo; Vendula Pospichalova; Zhiqing Huang; Susan K Murphy; Sturgis Payne; Fang Wang; Margaret Kennedy; George J Cianciolo; Vitezslav Bryja; Salvatore V Pizzo; Robin E Bachelder Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240
Authors: Trinidad Mata Balaguer; Angeles Gómez-Martínez; Pilar García-Morales; Javier Lacueva; Rafael Calpena; Lourdes Rocamora Reverte; Natividad Lopez Riquelme; Isabel Martinez-Lacaci; José A Ferragut; Miguel Saceda Journal: BMC Mol Biol Date: 2012-07-30 Impact factor: 2.946